Daily Equity Report 04 Sep 2019

1. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 DAILY EQUITY REPORT 04 THSEPTEMBER 2019 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

2. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report INDIAN FACE INDIAN MARKET CLOSE PREVIOUS ! 37332.79 INDIAN EQUITY BENCHMARK - Indian indices remained under pressure throughout the day and the final hour selling has dragged the benchmark indices to the day's low level NIFTY 11023.25 with Nifty finished below 10,800 level. At close, the Sensex CLOSE PREVIOUS was down 769.88 points or 2.06% at 36,562.91, while Nifty NIKKEI 20620.19 was down 225.40 points or 2.04% at 10,797.90. About 805 shares have advanced, 1596 shares declined, and 173 shares 25626.55 are unchanged. UltraTech Cement, Titan Company, ICICI 1965.69 Bank, IOC and Tata Steel were the top losers on the Nifty, SECTORIAL INDICES while gainers were Tech Mahindra, BPCL, Britannia CLOSE Industries and HCL Technologies. All the sectoral indices CNX 100 10925.20 ended lower led by the PSU Bank, metal, energy, infra, S&P CNX 500 pharma, FMCG, auto and IT. GLOBAL FACE CNX 200 ! BANK NIFTY 26824.15 -2.20 Asian Market - Asian markets finished mixed as of the most recent closing prices. The Shanghai Composite gained 0.21% and the Nikkei 225 rose 0.02%. The Hang Seng lost 0.39%. TOP GAINERS CLOSE CHANGE (%) ! U.S. Market – North and South American markets finished mixed as of the most recent closing prices. The Bovespa TECHM gained 0.61% and the S&P 500 rose 0.06%. The IPC lost 1.21%. - ! - European markets – European markets are lower today with shares in France off the most. The CAC 40 is down 0.49% while Germany's DAX is off 0.40% and London's FTSE 100 is TOP LOSERS CLOSE lower by 0.19%. -4.52 ULTRACEMC -4.37 ICICIBANK -4.35 TITAN -4.23 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

3. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NIFTY SPOT MARKET MOVERS UPSIDE STRATEGY SELL ON RISE SCRIPT CLOSE (%) 1.35 TECHM PIVOT POINTS P 10846 S3 10456 S2 10651 S1 R1 10919 R2 11040 RESISTANCE R1-10950 R2-11100 R3 11235 0.51 HCLTECH 10724 - - SUPPORT S1-10650 S2-10500 - - - MARKET MOVERS DOWNSIDE CLOSE (%) -4.52 -4.12 RELIANCE -3.85 -3.60 NET BUY (CR.) NET INSTITUTION SELL (CR) FII 6180.98 TREND STRATEGY SELL ON RISE 3078.47 PIVOT POINTS P 26981 SUPPORT NSE TOTALS S2 26450 S1 26630 R2 R3 28043 25919 27161 27512 RESISTANCE R1-27000 R2-27200 DECLINE S INDICES BANK NIFTY NIFTY 2 0 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

4. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report MARKET TALKS Biocon says USFDA issued Complete! Response Letter insulin Glargine ! Interglobe Aviation CFO Rohit Philip Rohit Philip, Chief Financial Officer of Interglobe Aviation (IndiGo) has resigned today, September 15, 2019. The Board of Directors of the company have approved the appointment of Aditya Pande as the Chief Financial Officer of the Company with effect from September 16, 2019, the company said in the press note. Aditya Pande is a member of the Institute of Chartered Accountants of India and Is graduate from Delhi University. Aditya has been associated with GE from the last 21 years. Aditya is presently associated with GE as "CFO-GE Healthcare" (India, Africa, ASEAN and Asia-Pacific). Additionally, he is also their Interim- CEO defining strategy, drive operations and grow profitability. Previously, he was "Group CFO-GE South Asia". His other significant previous roles in GE Include effective Biocon said in the press USFDA has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) fur Insulin Glargine filed by its partner Mylan. The CRL has been issued pending completion of the Corrective and (CAPAs) submitted to the USFDA observations made at the conclusion of the pre-approval inspection of our insulin manufacturing facility in Malaysia on June 2019. The CRL did not identify any outstanding scientific issues with the application. We remain confident of the quality of our application and do not anticipate any impact of this CRL on the commercial launch timing of our Insulin Glargine in the US, the company said in the release. Maruti Suzuki, VE Commercial Vehicles sales drop in August Maruti Suzuki India Limited total sales declined by 32.7% of 1.06 lakh units in August 2019 vs. 1.58 lakh units in August 2018. This includes 94,728 units in the domestic market, 2,333 units of domestic OEM sales and 9,352 units of exports, the company said in passenger vehicle sales were down 36.1% at 93,173 units from 1.45 lakh units vehicles during the corresponding period last year. note on August 31, that the Actions to the in response ! CFO-GE Healthcare South Asia, Financial Controller, GE- South Asia, Global Financial Planning & Analysis Leader- Genpact and VP Finance Operations GE International Services. During his long tenure at GE, Aditya also hd a stint in the USA for 2-years. Previous to GE, Aditya worked at Arthur Andersen for five years Capital the filing. Domestic ! Tata Motors domestic passenger vehicle sales falls 58% in August Tata Motors Limited announced its sales in the domestic & international market, for August 2019, which stood at 32,343 vehicles, compared to 62,688 units during August 2018. The auto company reported a 58% decline in its domestic passenger vehicle sales at 7,316 units in August. The company had sold 17,351 units in the same month last year, the company said in the press note. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

5. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NAME OF THE STOCK : CADILAHC DATE : 04/09/2019 SEGMENT : CASH CHART TYPE : Candlestick EXCHANGE : NSE TECHNICAL INDICATORS USED : VOLUME.MACD,RSI. CHART INVESTMENT ADVICE: CALL CS CALL:- BUY CADILAHC IN CASH ABOVE 229 TGT 234 SL 224 RATIONALE FOR ARRIVING INVESTMENT ADVICE : TECHNICAL VIEW : THE STOCK TECHINCALLY IS UP ,TAKING SUPPORT OF VOLUME.RESISTANCE IS BROKEN TODAY WITH HEAVY VOLUME.AS WELL AS A POSSIBILITY OF UPWARD MOVEMENT IS THERE. OTHER REASON IF ANY :- SHOWING STRENGTHS IN INTRADAY CHARTS AS WELL Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

6. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. DISCLAIMER The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. CapitalStars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk. CapitalStars Financial Research Private Ltd., Reserves all Rights. INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

7. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market. we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors. we provide intraday as well as delivery stock tips in NSE and BSE and commodity tips in MCX and NCDEX. Get our more services:- Mcx Tips Financial advisory company Sharemarket company Stock Tips Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

8. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. BRANCH OFFICE Capitalstars Financial Research Private Limited PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME NO.54,VIJAYNAGAR INDORE REGISTERED OFFICE PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE Email:-backoffice@capiltalstars.in Contact us :- 9977499927, 9039012727 Report Is Checked by Investment Advisor: Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.